Brief: Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
02/12/2025 13:18
Dec 2 (Reuters) - enGene Holdings Inc ENGN.O: ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTURING PILOT PROGRAM TO SUPPORT MANUFACTURING READINESS ENGENE HOLDINGS - FDA SELECTS DETALIMOGENE VORAPLASMID TO PARTICIPATE IN CHEMISTRY, MANUFACTURING, & CONTROLS DEVELOPMENT & READINESS PILOT PPROGRAM Source text: ID:nBw8kKSfxa Further company coverage: ENGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on enGene Therapeutics
See all newsBrief: Engene Reports Second Quarter 2026 Financial Results And Provides Business Update
enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026
Brief: Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares
Brief: enGene Reports First Quarter 2026 Financial Results and Provides Business Update